Transcranial ultrasound device for enhancing sleep in OUD
Ended Project Grant Awarded Last action
- Award ID
- R43DA055399
- Recipient
-
Attune Neurosciences, Inc. UEI ET2MB89ZSHH5
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $958,323
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Funding
-
- $638,882.00 Federal
- $319,441.00 Non-federal
- Place of performance
- Menlo Park, CA 94025, USA
Award details come from USAspending.gov.
Description
- Abstract
- The opioid use disorder (OUD) is a rapidly expanding health epidemic in the united states with little progress in treatment efficacy. Insufficient sleep represents the most severe and pervasive symptoms of both phases of withdrawal and persist despite treatment. Because sleep loss plays a key role in anxiety and daily routine, its disruption is a major factor in a patient's relapse evidenced by the higher incidence of relapse in OUD patients with sleep disorders. Sleep dysfunction in OUD is characterized by significant loss in slow wave sleep (SWS), which are critical components of the benefits of sleep. In patients with severe withdrawal, sleep may consist almost entirely of brief periods of rapid eye movement (REM) with sparse non-REM (nrem) sleep interrupted by numerous awakenings. Given the prevalence of poor sleep quality in OUD and the association with relapse, treatments enhancing the restful effects of sleep could reduce the rate of relapse. However, commonly prescribed sleep medications have sedative and hypnotic effects with a risk of dependency too great for patients with OUD. Thus, new interventions to augment sleep are a critical unmet medical need which could have an outsized influence on their life. Here, we build off of research in humans and animal models demonstrating that focused ultrasound can stimulate brain regions underlying SWS. We will design a wearable device integrating sleep recordings and steerable ultrasound arrays. Ultrasound arrays will target the thalamus, a core SWS structure, using MRI maps of patient's brains and skulls. We will design custom EEG analytics software for delivering the stimulus during the rising phase of slow waves to enhance wave amplitude, duration, and beneficial effects. We will perform a human factors study with OUD patients to assess comfort and usability for redesigning the wearable. Throughout the project we will interact with the FDA in efforts to gain approval for a phase II study with OUD patients.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $319,441 | $0 | |
| Original award | $319,441 | $319,441 |
Quick answers
Who received award R43DA055399?
R43DA055399 was awarded to Attune Neurosciences, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2021.
How much is award R43DA055399 worth?
$958,323 has been obligated on R43DA055399: $638,882 in federal funding and $319,441 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award